ClinicalTrials.gg

Program

clifutinib

Also written as “Clifutinib Besylate”, “Clifutinib” and “[14C]Clifutinib”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Sunshine Lake Pharma.

Furthest: phase 3, since Oct 14, 20225 company-led studies, 3 open or runningNext primary completion: Apr 23, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sunshine Lake Pharma53 open or runningphase 3since Oct 14, 2022Mar 22, 2021Apr 23, 2027phase 1 · NCT07341672

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2021First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04827069 · 75 enrolled · China
  2. Nov 12, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT05133882 · 133 planned · China
  3. Oct 14, 2022Phase 3 study in Leukemia, Myeloid, AcuteNCT05586074 · 324 planned · China
  4. Sep 22, 2025Phase 1 study in Healthy Adult MaleNCT07211165 · 6 enrolled · China
  5. Dec 23, 2025Phase 1 study in Healthy Adult SubjectNCT07341672 · 80 planned · China

Ahead

  1. Apr 23, 2027Primary completion: phase 1 study in Healthy Adult SubjectNCT07341672
  2. Nov 30, 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT05586074
  3. Dec 31, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05133882

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07341672Healthy Adult Subject · China1Not yet recruitingApr 23, 202780
NCT07211165Healthy Adult Male · China1CompletedNov 5, 20256
NCT05586074Leukemia, Myeloid, Acute · China3RecruitingNov 30, 2027324
NCT05133882Leukemia, Myeloid, Acute · China2RecruitingDec 31, 2027133
NCT04827069Leukemia, Myeloid, Acute · China1CompletedAug 21, 202375

How it is read

Names in the registry

  • “Clifutinib Besylate”, 2 entries
  • “Clifutinib”, 2 entries
  • “[14C]Clifutinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.